WO2021104355A1 - 杂环硼酸化合物的杂质及其控制方法 - Google Patents
杂环硼酸化合物的杂质及其控制方法 Download PDFInfo
- Publication number
- WO2021104355A1 WO2021104355A1 PCT/CN2020/131686 CN2020131686W WO2021104355A1 WO 2021104355 A1 WO2021104355 A1 WO 2021104355A1 CN 2020131686 W CN2020131686 W CN 2020131686W WO 2021104355 A1 WO2021104355 A1 WO 2021104355A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tartrate
- impurities
- dugliptin
- preparation
- impurity
- Prior art date
Links
- 239000012535 impurity Substances 0.000 title claims abstract description 109
- 238000000034 method Methods 0.000 title claims abstract description 28
- -1 heterocyclic boronic acid compounds Chemical class 0.000 title claims description 16
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 claims abstract description 58
- 238000002360 preparation method Methods 0.000 claims abstract description 28
- 238000003908 quality control method Methods 0.000 claims abstract description 7
- 238000011160 research Methods 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 239000013558 reference substance Substances 0.000 claims abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 66
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 31
- 238000006243 chemical reaction Methods 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 19
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 15
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 claims description 14
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 11
- 239000012141 concentrate Substances 0.000 claims description 11
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 6
- 230000003647 oxidation Effects 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 4
- 239000004210 ether based solvent Substances 0.000 claims description 4
- 239000007789 gas Substances 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 125000005620 boronic acid group Chemical group 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000011261 inert gas Substances 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000009776 industrial production Methods 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- 238000001514 detection method Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 238000001228 spectrum Methods 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000005984 hydrogenation reaction Methods 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000007810 chemical reaction solvent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 3
- DVJAMEIQRSHVKC-BDAKNGLRSA-N Dutogliptin Chemical compound OB(O)[C@@H]1CCCN1C(=O)CN[C@H]1CNCC1 DVJAMEIQRSHVKC-BDAKNGLRSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 229950003693 dutogliptin Drugs 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000007039 two-step reaction Methods 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- AXJXOZFACYIMBU-VSGBNLITSA-N (2r,3r)-1,4-dimethoxy-1,1,4,4-tetraphenylbutane-2,3-diol Chemical compound C=1C=CC=CC=1C(OC)([C@H](O)[C@@H](O)C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 AXJXOZFACYIMBU-VSGBNLITSA-N 0.000 description 1
- FUGIIBWTNARRSF-UWVGGRQHSA-N (5s,6s)-decane-5,6-diol Chemical compound CCCC[C@H](O)[C@@H](O)CCCC FUGIIBWTNARRSF-UWVGGRQHSA-N 0.000 description 1
- GWVWUZJOQHWMFB-UHFFFAOYSA-N 1,1,2-triphenylethane-1,2-diol Chemical compound C=1C=CC=CC=1C(O)(C=1C=CC=CC=1)C(O)C1=CC=CC=C1 GWVWUZJOQHWMFB-UHFFFAOYSA-N 0.000 description 1
- CKHLARJSOMXDKL-UHFFFAOYSA-N 1,2-dicyclohexylethane-1,2-diol Chemical compound C1CCCCC1C(O)C(O)C1CCCCC1 CKHLARJSOMXDKL-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- UEGKGPFVYRPVCC-UHFFFAOYSA-N 2,5-dimethylhexane-3,4-diol Chemical compound CC(C)C(O)C(O)C(C)C UEGKGPFVYRPVCC-UHFFFAOYSA-N 0.000 description 1
- HFQWSMQJOHUNAR-UHFFFAOYSA-N 2,6,6-trimethylbicyclo[3.1.1]hept-3-ene-1,2-diol Chemical compound C1C2(O)C(C)(C)C1C=CC2(O)C HFQWSMQJOHUNAR-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- GVKYDJCQMGKHJA-YYXZMQKJSA-N CC1(C)[C@H]2[C@]3(C)OB([C@H](CCC4)N4C(CN[C@H]4CNCC4)=O)O[C@@H]3C[C@@H]1C2 Chemical compound CC1(C)[C@H]2[C@]3(C)OB([C@H](CCC4)N4C(CN[C@H]4CNCC4)=O)O[C@@H]3C[C@@H]1C2 GVKYDJCQMGKHJA-YYXZMQKJSA-N 0.000 description 1
- 0 CC1(C)[C@]2[C@]3(C)OB([C@](CCC4)N4C(C*[C@@]4C*CC4)=O)O[C@@]3C[C@@]1C2 Chemical compound CC1(C)[C@]2[C@]3(C)OB([C@](CCC4)N4C(C*[C@@]4C*CC4)=O)O[C@@]3C[C@@]1C2 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XUPZAAXUGTYAPM-VEDVMXKPSA-N OC(CCC1)N1C(CN[C@H]1CNCC1)=O Chemical compound OC(CCC1)N1C(CN[C@H]1CNCC1)=O XUPZAAXUGTYAPM-VEDVMXKPSA-N 0.000 description 1
- XUPZAAXUGTYAPM-UHFFFAOYSA-P OC(CCC1)N1C(C[NH2+]C1C[NH2+]CC1)=O Chemical compound OC(CCC1)N1C(C[NH2+]C1C[NH2+]CC1)=O XUPZAAXUGTYAPM-UHFFFAOYSA-P 0.000 description 1
- IIGYZAIGNJGRJZ-YHMJZVADSA-N O[B+]C(CCC1)N1C(CN[C@H](CC1)CN1C=O)=O Chemical compound O[B+]C(CCC1)N1C(CN[C@H](CC1)CN1C=O)=O IIGYZAIGNJGRJZ-YHMJZVADSA-N 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- XEBCWEDRGPSHQH-UHFFFAOYSA-N diisopropyl tartrate Chemical compound CC(C)OC(=O)C(O)C(O)C(=O)OC(C)C XEBCWEDRGPSHQH-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention provides impurities (I) and (II) of the heterocyclic boronic acid compound dugliptin L-tartrate.
- the impurities (I) and (II) respectively have the following structures:
- Solvents used include: methylene chloride/ethyl acetate, methylene chloride/n-hexane, methylene chloride/isopropyl acetate, methylene chloride/methyl tert-butyl ether, methylene chloride/ethyl acetate/n-hexane Alkane, ethyl acetate, ethyl acetate/n-hexane, ethyl acetate/acetonitrile, tetrahydrofuran/n-hexane, isopropyl acetate/n-hexane, methanol/n-hexane, n-hexane, acetonitrile, methyl tert-buty
- the present invention also provides a method for preparing high-purity Gliptin L-tartrate. Using this method to prepare Gliptin L-tartrate can effectively control the generation of oxidative impurities and reduce the generation of other impurities. .
- This method uses the process route shown in the following formula and adopts the process conditions of steps (1)-(4):
- the ether extraction solvent used in step (4) is methyl tert-butyl ether.
- high-purity dogliptin L-tartrate refers to a dogliptin L-tartrate in which the sum of the content of impurities (I) and (II) is less than 0.15%, and the total impurities are less than 0.5%.
- the present invention has the following beneficial effects:
- Figure 5 is an HPLC chart of a product with an impurity content of 0.95% of RRT1.09 prepared in Experiment 1 in Comparative Example 1;
- the "boronic acid protecting group” refers to the part of the group that blocks or protects the function of boronic acid when a reaction involving other functional positions of a compound is carried out.
- a borate ester which is derived from an alcohol, such as (+)-pinenediol, pinacol, 1,2-dicyclohexyl-ethylene glycol, 1, 2-ethylene glycol, 2,2-diethanolamine, 1,3-propanediol, 2,3-propanediol, 2,3-butanediol, diisopropyl tartrate, 1,4-butanediol, diiso Propyl glycol, (S,S)-5,6-decanediol, 1,1,2-triphenyl-1,2-ethylene glycol, (2R,3R)-1,4-dimethyl Oxy-1,1,4,4-tetraphenyl-2,3-butanediol, methanol,
- alcohols with only a single hydroxyl group such as methanol
- R is an organic moiety derived from the alcohol (for example -B(OMe) 2 ).
- diols such as pinacol form cyclic boronic acid diesters with -B(OR) 2 in which the organic moiety (eg -C(Me) 2 -C(Me) 2 -) connects two oxygens.
- the volumes of experiments 1 and 2 are determined by referring to the feeding ratio of the corresponding materials in the patents CN101232890 and CN101679238 respectively.
- the test results show that in these two cases, the RRT1.09 impurities and total impurities are not well controlled. .
- Comparing experiments 3 and 4 it can be seen that the smaller the remaining volume of the system after each concentration in the post-treatment process, the slightly increased total impurities and RRT1.09 impurity content of the product. It can be seen from experiments 5 and 6 that under the same conditions, when 5 times the mass volume of EA is added each time after concentration, the RRT1.09 impurity content in the product is higher.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
提供了度格列汀L-酒石酸盐的杂质(I)、(II)及其制备方法。(I)和(II)为度格列汀L-酒石酸盐的氧化杂质,在度格列汀L-酒石酸盐制备及放置过程中均会产生。同时提供了工业化生产度格列汀L-酒石酸盐时,在降低总杂的同时控制杂质(I)和(II)含量的方法,提高了度格列汀L-酒石酸盐的质量标准,保证其用药安全。另外,杂质(I)和(II)作为参比标准或对照品,可用于度格列汀或其L-酒石酸盐原料药和/或制剂中的质量控制和研究。
Description
本发明属于医药分析及制备技术领域,具体涉及杂环硼酸化合物度格列汀L-酒石酸盐的杂质(I)和(II)、其制备方法,以及(I)和(II)的质量控制方法。
度格列汀L-酒石酸盐(Dutogliptin L-Tartrate)是选择性的DPP-IV抑制剂,目前处于临床阶段,可用于糖尿病患者的葡萄糖调控。度格列汀L-酒石酸盐为杂环硼酸化合物,其结构如下:
度格列汀L-酒石酸盐为白色至类黄色固体粉末,在甲醇中易溶,异丙醇中极微溶解。由于其具有很强的吸水性,其固体原料中包含约10%左右的水份。同时,度格列汀L-酒石酸盐性质不稳定,在酸性及碱性条件下均易降解产生杂质。
专利CN101232890、CN101679238及WO2010107809公开了度格列汀L-酒石酸盐的制备方法。将中间体(2-I)经氢化还原,去除N上的-Cbz保护基得到中间体(1-I),然后在苯硼酸溶液中将硼酸根封闭基团去除,同时与L-酒石酸成盐得到度格列汀L-酒石酸盐:
以上两步反应中,会产生多种杂质。但是目前尚未有文献报道度格列汀或其L-酒石酸盐的相关杂质及控制方法。本申请发明人在按照以上路线制备度格列汀 L-酒石酸盐时,发现两步反应均会产生相对保留时间RRT1.09(以度格列汀L-酒石酸盐的液相检测方法检测)的杂质。更重要的是,不同批次产生该杂质的量不同,且各种重结晶纯化条件对该杂质的去除能力均较差。若无法确定该杂质的结构,进一步推测其来源,则无法控制该杂质的含量,药品质量的稳定性无法得到保证。故确认表征该RRT1.09杂质的结构,并设法控制其含量具有非常重要的意义。
由于度格列汀在合成过程中产生的杂质较多,导致各个杂质的分离鉴定工作难度较大。由于该RRT1.09杂质产生的量不可控且与度格列汀极性相当,因此该杂质的分离鉴定工作存在很大难度,必须寻找合适的方法对其进行鉴定确认,以进一步对其进行含量控制。
发明内容
本发明的目的是提供杂环硼酸化合物度格列汀L-酒石酸盐的杂质(I)和(II),并且对制备度格列汀L-酒石酸盐的工艺进行优化,在控制该两个杂质含量的同时,得到总杂少的度格列汀L-酒石酸盐,使之能够同时满足工业化生产要求和药品质量规范。本发明提供了杂质(II)的制备方法,制得了杂质(II)。杂质(II)是杂质(I)的L-酒石酸盐,在检测条件下杂质(I)和(II)出峰位置相同,故杂质(I)和(II)可用作标准品或对照品用于检测度格列汀或其L-酒石酸盐原料药或制剂中杂质(I)和(II)的含量,以对其进行质量控制和研究。
本发明的目的可通过以下技术方案实现:
本发明提供杂环硼酸化合物度格列汀L-酒石酸盐的杂质(I)和(II),杂质(I)和(II)分别具有以下结构:
杂质(I)和(II)为氧化杂质,可在制备工艺中产生,同时度格列汀产品在放置过程中也会降解产生。为控制其含量,需要对制备工艺或储存条件进行研究控制。
本申请发明人制备度格列汀L-酒石酸盐的路线如下式所示:
在研究前期,为降低各杂质含量,本申请发明人对氢化反应所得产物的纯化进行了深入研究,尝试了多种溶剂在不同温度下的纯化效果。所使用的溶剂包括:二氯甲烷/乙酸乙酯、二氯甲烷/正己烷、二氯甲烷/乙酸异丙酯、二氯甲烷/甲基叔丁基醚、二氯甲烷/乙酸乙酯/正己烷、乙酸乙酯、乙酸乙酯/正己烷、乙酸乙酯/乙腈、四氢呋喃/正己烷、乙酸异丙酯/正己烷、甲醇/正己烷、正己烷、乙腈、甲基叔丁基醚、乙酸异丙酯。其中,用乙酸乙酯纯化时可取得最优效果,具体工艺和纯化参数如专利CN101232890中所记载。
然而,随着研究的不断进展和完善,当使用更适合的检测条件时,发现上述最优条件纯化后的产品中存在之前未检测出的多个杂质,故需要重新筛选纯化条件。
经过大量筛选实验,发现很难高收率高纯度地获得满意的氢化还原产物。只有在改变结晶过程,使用THF和乙酸乙酯混合溶剂重结晶,严格控制各结晶过程中的溶剂体积和温度,才可以获得相对较好地纯化效果。
但是,尽管经过严格控制,RRT1.09(相对于度格列汀的出峰位置)的杂质依然处于较高水平。并且,本申请发明人发现采用含四氢呋喃的溶剂重结晶时,该杂质的含量不降反增。再次使用其他溶剂,如乙酸乙酯、二氯甲烷等重结晶,该杂质的含量也不会有明显的降低。猜测该杂质可能为氧化杂质,由于四氢呋喃溶剂中含有过氧化物,导致用四氢呋喃纯化时该杂质含量升高。
为验证该推测,确认杂质结构,对该杂质进行了合成研究,最终确认了该杂质结构。
本发明同时提供了杂质(II)的制备方法,由度格列汀L-酒石酸盐经双氧水氧化制得:
在一种优选实施方式中,所述双氧水的浓度为0.1%,所述氧化是指在室温下反应90h以上。
杂质(II)的质谱图见附图1,从图1知其分子离子峰m/z=214.1540,为(M+H)
+峰,与杂质(II)游离碱的分子量理论值213.1477相符。
杂质(II)的核磁共振氢谱见附图2、碳谱见附图3。氢谱数据及碳谱数据能对结构式上的氢和碳进行合理归属。
以杂质(II)为对照品,久置于空气中的度格列汀L-酒石酸盐为样品,在度格列汀L-酒石酸盐检测条件下进样。经检测,杂质(II)的出峰位置与度格列汀主峰对应的RRT1.09的杂质基本重合,验证了RRT1.09的杂质即为氧化杂质。
杂质(II)在碱性条件下解离,去除其中的L-酒石酸即得杂质(I)。在检测时,杂质(I)和杂质(II)同时出峰。
为避免氧化杂质的产生,在氢化反应完成后,本申请发明人不再使用四氢呋喃等醚类溶剂纯化。同时,为满足产物纯度高及氧化杂质含量低的要求,需要继续优化工艺条件。
本发明还提供了一种制备高纯度度格列汀L-酒石酸盐的方法,使用该方法制备度格列汀L-酒石酸盐既可以有效控制氧化杂质的产生,同时又减少了其他杂质的生成。该方法使用下式所示的工艺路线,采用步骤(1)-(4)的工艺条件:
其中,PG为可催化氢化去除的胺基保护基,优选-Cbz、-PMB、-Bn;R
1、R
2为硼酸保护基,各自独立地选自甲基、乙基、正丙基、异丙基或正丁基,或 者R
1、R
2与所连接的氧原子一起与形成环硼酸二酯;
(1)、中间体2在10%重量的钯碳,7-10倍质量体积的甲醇,氢气压力为0.3-0.5MPa的条件下催化氢化;
(2)、将步骤(1)所得产物在惰性气体氛围下后处理:经微晶纤维素和无水硫酸钠过滤,将滤液减压浓缩除去部分溶剂,加入乙酸乙酯后继续浓缩,此浓缩过程循环3-4次;
(3)、步骤(2)所得浓缩后加入乙酸乙酯的溶液在0℃下析晶,得到中间体1;
(4)、中间体1在正己烷和水的混合溶液中,与苯硼酸和L-酒石酸反应,反应液经醚类溶剂萃取,制得度格列汀L-酒石酸盐。
在一种优选实施方式中,在步骤(1)的催化氢化反应过程中,用氢气置换反应体系气体。
本申请发明人发现,步骤(1)催化氢化反应过程中,会产生杂质PHX2044,其结构为:
在反应过程中通过用氢气置换反应体系的气体,如每小时进行一次,每次用氢气置换两遍,会远远降低该杂质的产生,提高氢化产物的纯度。
在一种优选的实施方式中,步骤(2)中的浓缩是指每次浓缩后的剩余体积为中间体2质量的1.5-3倍,优选1.5-2倍,更优选1.75倍;浓缩后加入乙酸乙酯的体积为中间体2质量的2-4倍,优选2.5倍。
在一种优选的实施方式中,步骤(4)中所用正己烷的体积为中间体1质量的8倍以上。
在一种优选的实施方式中,步骤(4)中使用的醚类萃取溶剂为甲基叔丁基醚。
本发明中高纯度的度格列汀L-酒石酸盐是指其中杂质(I)和(II)的含量之和小于0.15%,总杂小于0.5%的度格列汀L-酒石酸盐。
本发明提供的度格列汀L-酒石酸盐杂质(I)和(II),可用作标准品或对照品对度格列汀或其L-酒石酸盐原料药和/或制剂进行质量控制和研究。
与现有技术相比,本发明取得的有益效果有:
1)、本申请确认并表征了度格列汀L-酒石酸盐工业化生产中易产生的难控性氧化杂质(I)和(II);
2)、本申请制备并验证了氧化杂质的结构,为度格列汀L-酒石酸盐杂质检测定量及定性分析提供了参比或对照;
3)、本申请提供了一种度格列汀L-酒石酸盐的制备方法,该方法控制了杂质(I)和(II)的产生,同时保证了度格列汀及其L-酒石酸盐的纯度,提升了产品质量,对度格列汀用药安全具有非常重要的指导意义。
综上,本发明提供了度格列汀L-酒石酸盐难分离难控制性氧化杂质(I)和(II),其制备方法及其质量控制方法。解决了现有技术中无法分离得到该杂质,因此无法对其进行结构鉴定,进而无法对其进行质量控制的技术问题。保证了度格列汀L-酒石酸盐的质量稳定性及用药安全。
图1为实施例1制得的度格列汀L-酒石酸盐杂质(II)的高分辨质谱图;
图2为实施例1制得的度格列汀L-酒石酸盐杂质(II)的
1HNMR核磁图谱;
图3为实施例1制得的度格列汀L-酒石酸盐杂质(II)的
13CNMR核磁图谱;
图4为实施例1制得的度格列汀L-酒石酸盐杂质(II)的HPLC图;
图5为对比实施例1中试验1制得的RRT1.09杂质含量为0.95%的产品的HPLC图;
图6为对比实施例3中所得度格列汀含量99.71%,RRT1.09杂质的含量为0.08%的HPLC图。
下面结合具体实施对本发明做进一步的阐述,但这些实施例对本发明不构成 任何限制。
本发明所用中间体(2-I)参照专利CN101232890中的制备方法制得粗品,后经甲醇重结晶纯化制得,纯化收率约92%。
其他化合物或试剂为本公司通过常规方法制备或市售购得。
“硼酸保护基”是指在进行涉及化合物的其它功能位置的反应时,阻滞或保护硼酸功能的基团部分。通常,硼酸羟基基团作为硼酸酯被保护,所述硼酸酯由醇衍生,例如(+)-蒎烷二醇、频哪醇、1,2-二环己基-乙二醇、1,2-乙二醇、2,2-二乙醇胺、1,3-丙二醇、2,3-丙二醇、2,3-丁二醇、二异丙基酒石酸酯、1,4-丁二醇、二异丙基乙二醇、(S,S)-5,6-癸二醇、1,1,2-三苯基-1,2-乙二醇,(2R,3R)-1,4-二甲氧基-1,1,4,4-四苯基-2,3-丁二醇、甲醇、乙醇、异丙醇、儿茶酚或1-丁醇等。本领域技术人员将理解,仅具有单羟基的醇,例如甲醇形成具有-B(OR)
2的二酯,其中R是来自醇的有机部分(例如-B(OMe)
2)。相比而言,二醇例如频哪醇形成具有-B(OR)
2的环硼酸二酯,其中有机部分(例如-C(Me)
2-C(Me)
2-)连接两个氧。
-Cbz:苄氧羰基;
-PMB:对甲氧基苄基;
-Bn:苄基。
实施例1 杂质(II)的制备
反应瓶中加入2g度格列汀L-酒石酸盐和100mL 0.1%的双氧水溶液,室温下放置至少90h。将样品于-18℃下冻干,得到1g杂质(II)。
杂质(II)在碱性条件下解离,去除其中的L-酒石酸即得杂质(I)。在检测时,杂质(I)和杂质(II)同时出峰。
将所得杂质(II)进行结构鉴定,得到以下数据:
MS(ESI)m/z=214.1540(M+H)
+,与杂质(II)游离碱的分子量213.1477相符。谱图见附图1。
1H NMR(500MHz,D
2O)δ5.75(s,1H),5.39(s,1H),4.27(s,2H),4.10-4.08(m,1H),4.06-4.02(m,1H),3.95(s,1H),3.72-3.68(m,1H),3.55-3.50(m,3H),3.38-3.27(m,2H),2.51-2.44(m,1H),2.18-2.14(m,1H),1.94-1.86(m,3H),谱图见附图2。
13C NMR(500MHz,D
2O)δ178.10,166.06,165.90,81.14,80.62,55.83,47.49,47.46,47.18,47.14,45.88,45.38,34.43,32.34,27.62,22.07,20.15,谱图见附图3。
所得杂质(II)经HPLC检测纯度为98.17%,谱图见附图4。
实施例2 高纯度度格列汀L-酒石酸盐的制备
1)、氢化反应
反应釜中加入中间体(2-I)(5.7Kg)、5%湿Pd/C(0.57Kg)和甲醇(43L)。用氮气置换体系空气三次,再用氢气置换3次。氢气压力0.5MPa下,室温反应,体系压力降至0.3MPa时补加氢气至压力0.5MPa,反应体系每隔一小时用氢气置换2次,反应5h。
在加压过滤器中填入微晶纤维素和无水硫酸钠,将反应液用氮气加压过滤,并用甲醇冲洗,合并滤液,氮气保护下减压浓缩至剩余体积约10L,加入14L乙酸乙酯,此时混合物为牛奶状浑浊液,继续浓缩至剩余体积约10L,加入14L乙酸乙酯,再次浓缩至剩余体积约10L,加入14L乙酸乙酯,继续浓缩至剩余体积约10L。加入14L乙酸乙酯将残留物降温至0℃搅拌约40min,趁低温过滤,滤饼用0℃的乙酸乙酯(5.7L)淋洗,抽干,室温下真空干燥4h得白色粉末状中间体(1-I)。
2)、脱保护及成盐反应
将中间体(1-I)(2.5Kg),L-酒石酸(1Kg)和水(7L)加入50L反应釜中,室温下搅拌反应1.5h后向反应釜中加入苯硼酸(850g)和正己烷(25L),继续搅拌3h。将反应液转移至萃取罐中,用MTBE(12.5L×3)萃取,弃去有机相,水相减压浓缩除去其中残留的MTBE。
将所得溶液经滤膜过滤后喷雾干燥,得到白色固体度格列汀L-酒石酸盐(收率:79.8%)。
实施例3高纯度度格列汀L-酒石酸盐的大量制备
1)、氢化反应
反应釜中加入中间体(2-I)(70kg)、5%湿Pd/C(7Kg)和甲醇(500L)。用氮气置换体系空气三次,再用0.5MPa的氢气置换3次,室温搅拌反应,体系压力降至0.3MPa时补加氢气至压力0.5MPa,反应体系每隔一小时用氢气置换2次,反应7h,终止反应。
在加压过滤器中填入微晶纤维素和无水硫酸钠,将反应液用氮气加压过滤,并用甲醇冲洗。合并滤液,氮气保护下减压浓缩至,加入乙酸乙酯(180L),此时混合物为牛奶状浑浊液,继续浓缩至剩余体积约140L,重复此操作3次至浓缩至剩余体积约140L。加入乙酸乙酯(180L),降温至0℃搅拌约40min,趁低温 过滤,滤饼用0℃乙酸乙酯(70L)淋洗,抽干,室温下真空干燥5h得白色粉末状中间体(1-I)。
2)、脱保护及成盐反应
将中间体(1-I)(30Kg),L-酒石酸(12Kg)和水(60L)加入反应釜中,室温搅拌2h。向反应釜中加入苯硼酸(10Kg)和正己烷(250L),继续搅拌3h。将反应液转移至萃取罐中,静置分层,弃去有机相,水相用MTBE(300L×3)萃取。干燥,过滤,滤液减压浓缩除去残留的MTBE。
将所得溶液经滤膜过滤,喷雾干燥,得白色固体度格列汀L-酒石酸盐(收率:85%)。
对比实施例1
取相同质量的中间体(2-I),改变实施例2氢化反应中反应溶剂的体积、后处理过程中体系每次浓缩后的体积或每次浓缩后加入EA的体积,其他条件不变,按照实施例2进行反应,试验结果见表1。
表1
试验1和2的各体积为分别参照专利CN101232890和CN101679238中相应各物料的加料比例关系确定,由试验结果可知,在该两种情况下,RRT1.09杂质和总杂均没有得到很好地控制。对比试验3和4可知,后处理过程中体系每次浓缩后的剩余体积越小,产品的总杂和RRT1.09杂质含量稍有增加。由试验5和6可知,同等条件下,浓缩后每次加入5倍质量体积的EA时,产物中RRT1.09杂质含量较多。对比试验7和8可知,反应溶剂体积的变化对RRT1.09杂质的影响较小,但对反应总杂的影响较大,增大反应溶剂体积,可降低总杂。整体而言,在7-9倍中间体(2-I)质量体积的反应溶剂、1.5-2倍质量体积的浓缩体积及加入2-4倍质量体积的EA的条件下,可以取得较满意的结果。
在大量制备时,由于样品溶解等因素,实际使用的条件为7-10倍中间体(2-I)质量体积的反应溶剂、1.5-3倍中间体(2-I)质量体积的浓缩体积及加入2-4倍中间体(2-I)质量体积的EA时均可以取得较好的实验结果。
对比实施例2
比较实施例2氢化反应在反应过程中是否用氢气置换体系气体的反应效果,其他条件采用对比实施例1中试验3的条件,得到如下表2所示的结果:
表2
其中,杂质PHX2044具有以下结构:
对比实施例3
改变实施例2脱保护及成盐反应中反应时的有机溶剂和后处理使用的萃取溶剂,按照对比实施例1中试验3的条件进行反应,不同试验得到的结果见下表3:
表3
为控制氧化杂质生成,整个工艺过程中应尽量避免使用醚类溶剂。使用正己烷作溶剂可以减少一部分氧化杂质的产生。实际上,用环己烷作溶剂与正己烷作溶剂时效果相当,但是环己烷较粘稠,更难和水混合均匀,导致反应时间长。该反应同时还需考虑苯硼酸的去除,使用正己烷或环己烷萃取均有大量苯硼酸残留,考虑到萃取过程用时较短,故仍采用MTBE萃取,试验结果也可满足要求。
实施例4 度格列汀L-酒石酸盐中RRT1.09杂质的检测
色谱条件:
流动相:25mmol/L SDS水溶液∶乙腈∶三氟乙酸=600∶400∶1为流动相A,25mmol/L SDS水溶液∶乙腈∶三氟乙酸=400∶600∶1为流动相B;
柱温:60±5℃;
流速:1.0mL/min;
进样量:60uL;
检测波长:210nm;
洗脱条件如下表4所示:
时间(分钟) | 流动相A(%V/V) | 流动相B(%V/V) |
0 | 100 | 0 |
25 | 100 | 0 |
45 | 0 | 100 |
60 | 0 | 100 |
60.1 | 100 | 0 |
70 | 100 | 0 |
1、溶液配制及检测
A、供试品溶液的制备:
取度格列汀L-酒石酸盐适量,精密称定,加流动相A溶解并制成每1mg中约含度格列汀L-酒石酸盐0.8mg的溶液,作为供试品溶液;
精密量取供试品溶液1mL,置100mL量瓶中,用溶剂稀释至刻度,作为自身对照溶液;
B、分离度溶液的制备:
另称取度格列汀L-酒石酸盐约8mg,置10mL量瓶中,加0.1%双氧水1.0mL放置10分钟,加溶剂稀释至刻度,作为分离度溶液;
C、检测方法:
取60μL分离度溶液注入液相色谱仪,要求主峰和RRT1.09杂质的分离度不小于1.0。再精密量取供试品溶液和自身对照溶液各60μL,分别注入液相色谱仪,记录色谱图。按自身对照法计算RRT1.09杂质的含量。
以上实施例的说明只是用于帮助理解本发明的方法及其核心思想。应当指出,对于本领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以对本发明进行若干改进和修饰,这些改进和修饰也落入本发明权利要求的保护范围内。
Claims (10)
- 如权利要求2所述的制备方法,其特征在于:所述双氧水的浓度为0.1%,所述氧化为在室温下反应90h以上。
- 一种降低权利要求1所述杂质(I)和(II)含量的制备度格列汀L-酒石酸盐的方法,其特征在于:按下式所示路线制备度格列汀L-酒石酸盐时,其中,PG为可催化氢化去除的胺基保护基,优选-Cbz、-PMB、-Bn;R 1、R 2为硼酸保护基,各自独立地选自甲基、乙基、正丙基、异丙基或正丁基,或者R 1、R 2与所连接的氧原子一起形成环硼酸二酯;采用如下步骤:(1)、中间体2在10%重量的钯碳,7-10倍质量体积的甲醇,氢气压力为0.3-0.5MPa的条件下进行催化氢化反应;(2)、将步骤(1)所得产物在惰性气体氛围下后处理:经微晶纤维素和无水硫酸钠过滤,将滤液减压浓缩除去部分溶剂,加入乙酸乙酯后继续浓缩,此浓缩过程循环3-4次;(3)、步骤(2)所得浓缩后加入乙酸乙酯的溶液在0℃下析晶,得到中间体1;(4)、中间体1在正己烷和水的混合溶液中,与苯硼酸和L-酒石酸反应,反应液经醚类溶剂萃取,制得度格列汀L-酒石酸盐。
- 如权利要求4所述的制备方法,其特征在于:步骤(1)中所述的催化氢化反应,在反应过程中用氢气置换反应体系气体。
- 如权利要求4所述的制备方法,其特征在于:步骤(2)中所述浓缩为浓缩至剩余体积为中间体2质量的1.5-3倍,优选1.5-2倍,更优选1.75倍;浓缩后加入乙酸乙酯的体积为中间体2质量的2-4倍,优选2.5倍。
- 如权利要求4所述的制备方法,其特征在于:步骤(4)中所用正己烷的体积为中间体1质量的8倍以上。
- 如权利要求4所述的制备方法,其特征在于:步骤(4)中所述醚类溶剂为甲基叔丁基醚。
- 如权利要求1所述的杂质(I)和(II),用作标准品或对照品对度格列汀或其L-酒石酸盐原料药和/或制剂进行质量控制和研究的用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911198317.XA CN111533675B (zh) | 2019-11-29 | 2019-11-29 | 杂环硼酸化合物的杂质及其控制方法 |
CN201911198317.X | 2019-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021104355A1 true WO2021104355A1 (zh) | 2021-06-03 |
Family
ID=71952072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/131686 WO2021104355A1 (zh) | 2019-11-29 | 2020-11-26 | 杂环硼酸化合物的杂质及其控制方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111533675B (zh) |
WO (1) | WO2021104355A1 (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060264400A1 (en) * | 2003-11-12 | 2006-11-23 | Campbell David A | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-iv |
CN1894261A (zh) * | 2003-11-12 | 2007-01-10 | 芬诺密克斯公司 | 杂环硼酸化合物 |
CN101232890A (zh) * | 2005-08-01 | 2008-07-30 | 芬诺密克斯公司 | 制备杂环硼酸及其衍生物的方法 |
CN101522201A (zh) * | 2006-08-30 | 2009-09-02 | 芬诺密克斯公司 | Dpp-iv抑制剂的固体柠檬酸盐和酒石酸盐 |
CN101679238A (zh) * | 2007-03-08 | 2010-03-24 | 芬诺密克斯公司 | 用于合成选择性dpp-iv抑制剂的方法和中间体 |
US20100240611A1 (en) * | 2009-03-17 | 2010-09-23 | Matthew Ronsheim | Methods for preparing dpp-iv inhibitor compounds |
-
2019
- 2019-11-29 CN CN201911198317.XA patent/CN111533675B/zh active Active
-
2020
- 2020-11-26 WO PCT/CN2020/131686 patent/WO2021104355A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060264400A1 (en) * | 2003-11-12 | 2006-11-23 | Campbell David A | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-iv |
CN1894261A (zh) * | 2003-11-12 | 2007-01-10 | 芬诺密克斯公司 | 杂环硼酸化合物 |
CN101232890A (zh) * | 2005-08-01 | 2008-07-30 | 芬诺密克斯公司 | 制备杂环硼酸及其衍生物的方法 |
CN101522201A (zh) * | 2006-08-30 | 2009-09-02 | 芬诺密克斯公司 | Dpp-iv抑制剂的固体柠檬酸盐和酒石酸盐 |
CN101679238A (zh) * | 2007-03-08 | 2010-03-24 | 芬诺密克斯公司 | 用于合成选择性dpp-iv抑制剂的方法和中间体 |
US20100240611A1 (en) * | 2009-03-17 | 2010-09-23 | Matthew Ronsheim | Methods for preparing dpp-iv inhibitor compounds |
Also Published As
Publication number | Publication date |
---|---|
CN111533675A (zh) | 2020-08-14 |
CN111533675B (zh) | 2021-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103261142B (zh) | 曲前列环素的制备 | |
CN109705124B (zh) | 一种放射性氟标记Larotrectinib化合物及其制备方法 | |
KR20100016116A (ko) | 개선된 솔리페나신의 합성공정 | |
JP2021501191A (ja) | Wee1阻害剤としての大環状化合物及びその使用 | |
WO2016086158A1 (en) | Opioid receptor modulators | |
JP2021529214A (ja) | キノリノピロリジン−2−オン系誘導化合物及びその使用 | |
CN115286521B (zh) | 一种盐酸左沙丁胺醇的合成方法 | |
EP3785713A1 (en) | Salt of cetagliptin, preparation method therefor, pharmaceutical composition, and use thereof | |
WO2021104355A1 (zh) | 杂环硼酸化合物的杂质及其控制方法 | |
CN104557845B (zh) | 一种鲁比前列酮化合物的制备方法 | |
CN102190658A (zh) | 一类抗肿瘤海洋天然产物ecteinascidins的结构类似物 | |
EP4159719A1 (en) | Preparation method for (s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)methyl propionate diacid salt | |
CN103193763B (zh) | 一种来那度胺的制备方法 | |
CN107743488B (zh) | 2-氧代-1,3,8-三氮杂螺[4.5]癸烷-3-基]甲酸衍生物 | |
CN103467449B (zh) | 一种哌啶衍生物、制备方法及在制备常山酮中的应用 | |
CN113480480B (zh) | 一种(r)-5’-甲氧基劳丹素的合成方法 | |
CN109776372A (zh) | 维格列汀有关物质及其制备方法 | |
ES2716574T3 (es) | Un método de preparación de oxicodona | |
CN111718344A (zh) | 一种他达拉非的精制方法 | |
TW202304931A (zh) | 生物素之製造方法,以及生物素之l-離胺酸鹽及其製造方法 | |
KR20200022648A (ko) | 가도부트롤의 제조방법 | |
EP4163271A1 (en) | Method for preparing methyl (s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenylpropionate and salt thereof | |
CN109879800B (zh) | 一种贝他斯汀药物中间体的制备工艺 | |
CN110804026B (zh) | 1- (3- (3-(4-氯苯基)丙氧基)丙基)哌啶盐酸盐的合成方法 | |
CN107459524B (zh) | 一种双氮氧杂环螺二酮哌嗪骨架类化合物及其构建方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20893070 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20893070 Country of ref document: EP Kind code of ref document: A1 |